Proposal to list a range of medical devices used in the prevention of venous thromboembolisms (VTE Prevention) supplied by Mӧlnlycke Health Care Pty Limited

Hospital devices Consultation Closed

What we are proposing

PHARMAC is seeking feedback on a proposal to list a range of VTE Prevention products in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018 through a provisional agreement with Mӧlnlycke Health Care Pty Limited (“Mӧlnlycke”).

Consultation closes at 4pm on Wednesday, 28 March 2018 and feedback can be emailed to

What would the effect be?

From 1 May 2018, Mӧlnlycke’s range of VTE Prevention products would be listed under a proposed national agreement that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate. (“Agreement”)

This Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of VTE Prevention products.

Mӧlnlycke’s range of VTE Prevention products are new to DHB Hospitals so there would be no financial impact based on current purchasing patterns as a result of this proposal.

Who we think will be interested

  • Suppliers and wholesalers
  • DHB staff
    • Clinicians
    • Procurement Officers

About VTE prevention products

The risk of events related to VTE, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), increase following prolonged confinement following surgery or illness. VTE Prevention products include Graduated Compression Stockings, Intermittent Pneumatic Compression devices and Venous Foot Pump devices.

Why we’re proposing this

In 2016 PHARMAC issued a Request for Proposals (“RFP”) for VTE Prevention products. The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements and this proposal is the latest to arise from that process. We expect to consult on further proposed agreements with other suppliers over the next few months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Mӧlnlycke for the supply of VTE Prevention products to DHBs. This would result in listing 15 products, in the Brevet tx range, in the Pharmaceutical Schedule from 1 May 2018.

Brevet tx is new to DHB Hospitals, but has been used in DHB like settings overseas, and the Agreement would provide an increased range of Graduated Compression Stockings from which clinicians could choose.

The full list of products in the proposal is attached to this consultation. Pricing has been made available to appropriate DHB personnel.

DHBs would be able to continue to choose which VTE Prevention products they procure.

The Agreement includes provisions for providing educational services that would be tailored to the individual needs of DHB Hospitals, in formats and at times as required by DHB Hospitals.

Pricing for the products in the Agreement, subject to any prior termination of the Agreement, would not be increased before 1 May 2021.

To provide feedback

Send us an email: by 4pm, Wednesday 28 March 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.